Table 1.
Clinical Data Table
| Total | Non-responder | Responder | P-value | |
|---|---|---|---|---|
| 52 | 27 (52%) | 25(48%) | ||
| Immunotherapy Treatment | ||||
| Nivolumab | 36 (69%) | 19 (70%) | 17 (68%) | 0.98 |
| Pembrolizumab | 14 (27%) | 7 (26%) | 7 (28%) | |
| Atezolizumab | 2 (4%) | 1 (4%) | 1 (4%) | |
| Histology | ||||
| Adenocarcinoma | 33 (63%) | 17 (63%) | 16 (64%) | 0.94 |
| Squamous | 19 (37%) | 10 (37%) | 9 (36%) | |
| Driver Mutation* | ||||
| Yes | 9 (17%) | 6 (22%) | 3 (12%) | 0.47 |
| Gender | ||||
| Male | 23 (44%) | 12 (44%) | 11 (44%) | 0.97 |
| Female | 29 (56%) | 15 (56%) | 14 (56%) | |
| Age at Diagnosis | ||||
| Median | 62 | 62 | 63 | 0.59 |
| Age at ICB Initiation | ||||
| Median | 64 | 64 | 65 | 0.79 |
| Smoking History | ||||
| Former/Current | 44 (85%) | 23 (85%) | 21 (84%) | 0.91 |
| Never | 8 (15% | 4 (15%) | 4 (16%) | |
| Smoking (Pack Years) | ||||
| Median | 20 | 25 | 20 | 0.77 |
| PFS (mo) | ||||
| Events | 42 | 27 | 15 | <0.001 |
| Median | 3.3 | 1.7 | 25 | |
| OS (mo) | ||||
| Events | 41 | 25 | 16 | <0.001 |
| Median | 9.6 | 6.0 | 25 | |
Age at ICB: Age at time of starting immunotherapy; PFS (mo): Progression-free Survival in months; OS (mo): Overall survival in months
*
Driver mutations were defined as actionable EGFR mutations or EML4-ALK fusions
Footnote: Fisher’s exact test for categorical variables, t-test or median test for continuous variables, log-rank test for PFS and OS.